Where is Novartis AG (NVS) Headed?

Novartis AG (NYSE:NVS) is one of the best immunotherapy stocks to buy according to hedge funds. Novartis AG (NYSE:NVS) announced on February 13  final results from the Phase III ALIGN study, stating that Vanrafia (atrasentan) showed a positive difference in eGFR change from baseline vs. placebo at Week 136 in the ALIGN study, 4 weeks after study treatment ended, with results favoring Vanrafia across multiple timepoints, measures of kidney function, and in patients additionally receiving SGLT2 inhibitors. M ...